SCHEMBL16184382

SCHEMBL16184382

CNc1nc(-c2cnccn2)nc2c(F)cc(-c3ccc(Cl)cc3F)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAT2A P31153 3/20 0.39
▸ ALOX5AP P20292 2/20 0.38
▸ FEN1 P39748 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NR1I2 O75469 1/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ PTGES2 Q9H7Z7 1/20 0.37
▸ TGFBR1 P36897 2/20 0.36
▸ PRKD3 O94806 1/20 0.36
▸ PRKD1 Q15139 1/20 0.36
▸ PRKD2 Q9BZL6 1/20 0.36
▸ PDE2A O00408 1/20 0.35
▸ CLK1 P49759 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184375 0.93 TGFBR1 (0.41) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184365 0.90 FEN1 (0.41) ALOX5APFEN1NPC1RAB9ATGFBR1
SCHEMBL16184369 0.89 NPC1 (0.44) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184381 0.87 NPC1 (0.51) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184362 0.86 FEN1 (0.42) ALOX5APFEN1NPC1TGFBR1CYP1A2
SCHEMBL16184370 0.86 MAP4K4 (0.45) MAT2ANPC1RAB9APKMTGFBR1
SCHEMBL16184374 0.86 NPC1 (0.44) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184372 0.86 CYP1A2 (0.42) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184367 0.85 NPC1 (0.39) MAT2AALOX5APFEN1NPC1RAB9A
SCHEMBL16184215 0.85 MAT2A (0.41) MAT2AALOX5APFEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB MAT2A 2203/4885ALOX5AP 2918/4885FEN1 3258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback